Refine
Has Fulltext
- yes (61)
Is part of the Bibliography
- yes (61) (remove)
Year of publication
- 2020 (61) (remove)
Document Type
- Journal article (45)
- Doctoral Thesis (16)
Keywords
- multiple myeloma (10)
- Aspergillus fumigatus (4)
- relapse (4)
- B cells (3)
- refractory (3)
- 18F-FDG PET/CT (2)
- Akute Leukämie (2)
- HIV (2)
- Lopinavir (2)
- Multiples Myelom (2)
- NAFLD (2)
- Therapeutisches Drug Monitoring (2)
- Vitamin D (2)
- cancer (2)
- inflammation (2)
- management (2)
- mortality (2)
- stem cell transplantation (2)
- 11C-Methionine PET/CT (1)
- 3D culture (1)
- 68Ga-Pentixafor PET/CT (1)
- AKT-signaling (1)
- ALiOS (1)
- ASE formula (1)
- Adaptive cell transfer (1)
- Adhärenz (1)
- Adipositas (1)
- Allogene Stammzelltransplantation (1)
- Allogeneic stem cell transplantation (1)
- Antimykotika (1)
- Antimykotikum (1)
- Arzneimittelüberwachung (1)
- Aspergillose (1)
- Aspergillus fumigatus-spezifische CD154+/CD4+ Zellen (1)
- Aspergillus sp. (1)
- Autologous hematopoietic stem cell transplantation (1)
- B cell (1)
- Bariatrische Operation (1)
- Bauchspeicheldrüsenkrebs (1)
- Bewältigungsfähigkeiten (1)
- Blutkontakt (1)
- CAR T cell (1)
- CAR T cells (1)
- CCL3 (1)
- CCL4 (1)
- CCL5 (1)
- CCS (1)
- CD38 (1)
- CMV reactivation (1)
- COX2 expression (1)
- Candida sp. (1)
- Capecitabin (1)
- Chimerism (1)
- Chimärismus (1)
- Coronavirus Disease 2019 (1)
- Depression (1)
- Donor lymphocytes (1)
- EGFR (1)
- Efavirenz (1)
- Effektorfunktionen (1)
- Einstellung zum Tod (1)
- Emotionsregulierung (1)
- Extraktionskontrolle (1)
- Fettleber (1)
- Fettsucht (1)
- Granulozyt (1)
- HB-EGF (1)
- HGF (1)
- HNSCC (1)
- Humanserum (1)
- Hämostase (1)
- Immunsuppressiva (1)
- Infectious complications (1)
- Infektiologie (1)
- Infektion (1)
- Invasive Aspergillose (1)
- Invasive Mykosen (1)
- JCV (1)
- KRAS (1)
- Kinder (1)
- Kinderheilkunde (1)
- Knochenmarktransplantation (1)
- Kontamination (1)
- Körperflüssigkeit (1)
- Lymphatische Leukämie (1)
- MAPKAPK2 (1)
- MEK/ERK-signaling (1)
- MOR202 (1)
- MYC (1)
- Megakaryozyt (1)
- Met (1)
- Mikrobiom <Genetik> (1)
- Myeloma (1)
- Mykose (1)
- NASH (1)
- NGS (1)
- NLRP3 (1)
- NRF2 (1)
- Nadelstichverletzungen (1)
- Nevirapin (1)
- PCR (1)
- PD-L1 (1)
- PML (1)
- POU6F2-AS2 (1)
- Pankreaskarzinom (1)
- Pankreaskarzinomzentrum (1)
- Pom‐PAD‐Dara (1)
- Prodigy (1)
- Progredienzangst (1)
- Prävention (1)
- Psychoneuroimmunologie (1)
- RT-PCR (1)
- Radiochemotherapy (1)
- Real time quantitative PCR (1)
- Rectal cancer (1)
- Rhizopus arrhizus (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Spender-Chimärismus (1)
- Stammzelltransplantation (1)
- Surgery (1)
- Systemic sclerosis (1)
- Säuglinge (1)
- Südafrika (1)
- T cell (1)
- T cells (1)
- TLR agonists (1)
- TNFSF14 (1)
- TNFSF4 (1)
- TSLP (1)
- Tdp-43 (1)
- Teichholz formula (1)
- Therapeutic Drug Monitoring (1)
- Time interval (1)
- VCE (1)
- Verhalten und Verhaltensmechanismen (1)
- Versorgungsrealität (1)
- Western diet (1)
- Zink (1)
- Zukunftsangst (1)
- acute leukemia (1)
- acute lymphoblastic leukaemia (1)
- acute lymphoblastic leukemia (1)
- acute respiratory distress syndrome (1)
- adalimumab (1)
- adherence (1)
- adverse events (1)
- allogene Stammzelltransplantation (1)
- amplicon sequencing (1)
- amyotrophic lateral sclerosis (1)
- anticoagulation (1)
- antithrombotic therapy (1)
- anxiety (1)
- atrial fibrillation (1)
- attitude to death (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- axonal transcriptome (1)
- behavior and behaviormechanisms (1)
- binding (1)
- blinatumomab (1)
- bone (1)
- bone marrow angiogenesis (1)
- bridging (1)
- c-ART (1)
- c-ART Kinder (1)
- cancer vaccines (1)
- capecitabine (1)
- capture (1)
- carfilzomib (1)
- cfRNA (1)
- chimeric antigen receptor (1)
- clinical trial (1)
- colonoscopy (1)
- common variable immunodeficiency (1)
- complications (1)
- coping skills (1)
- corticosteroids (1)
- cytokines (1)
- daratumumab (1)
- ddPCR (1)
- definition (1)
- dendritic cells (1)
- depression (1)
- discharge definition (1)
- donor-cell leukemia (1)
- drug screening (1)
- early detection (1)
- echocardiography (1)
- emotional regulation (1)
- endothelial cells (1)
- extramedullary disease (1)
- fear of cancer (1)
- fear of progression (1)
- fluorescence (1)
- fungal aerosolization (1)
- fungal infection (1)
- fungal infections (1)
- galactomannan (1)
- gene (1)
- genetic susceptibility (1)
- growth differentiation factor 15 (1)
- head and neck cancer (1)
- helicase (1)
- hematologic malignancies (1)
- hematological malignancies (1)
- hemodialysis (1)
- immune response (1)
- immune therapy (1)
- immunity (1)
- immuno-oncology (1)
- immunotherapeutics (1)
- immunotherapy (1)
- incidence (1)
- inflammasome (1)
- inflammation-induced tissue demage (1)
- interacts (1)
- interleukin 1 (1)
- interleukin 18 (1)
- invasive aspergillosis (1)
- kinease (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- lenalidomide (1)
- lentiviral transduction (1)
- life-threatening side-effects (1)
- liquid biopsy (1)
- low molecular heparin (1)
- lymphocytes (1)
- mantle cell lymphoma (1)
- mechanosensing (1)
- mechanotransduction (1)
- melanoma malignancy (1)
- memory B cells (1)
- metabolic tumor volume (MTV) (1)
- methionine (1)
- microbiota (1)
- molecular diagnosis (1)
- monocytes (1)
- multiplex PCR (1)
- muscle (1)
- music (1)
- mycosis (1)
- myokines (1)
- nOAC (1)
- natural killer cell (1)
- newly diagnosed (1)
- nicotinamide (1)
- novel therapies (1)
- nuclear receptors (1)
- nucleotide excision repair (1)
- obinutuzumab (1)
- oral anticoagulants (1)
- organoids (1)
- osteokines adaptation (1)
- pancreatectomy (1)
- pancreatic adenocarcinoma (1)
- pathophysiology (1)
- pattern (1)
- personalised medicine (1)
- porcine large animal model (1)
- postoperative bleeding (1)
- pre-clinical models (1)
- primary immunodeficiencies (1)
- progression (1)
- prostaglandin E2 (1)
- psychischer Stress (1)
- psychological distress (1)
- psychoneuroimmunology (1)
- pulmonary immune response (1)
- radiogenomics (1)
- recognition (1)
- recurrence (1)
- relaxation (1)
- rheumatoid arhritis (1)
- safety (1)
- serum biomarkers (1)
- small bowel bleeding (1)
- smoldering myeloma (1)
- stress level (1)
- subunit (1)
- sulfur (1)
- superior (1)
- surgical care (1)
- t-lymphocytes (1)
- thromboembolism (1)
- tocilizumab (IL-6 inhibitor) (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- toxicity (1)
- transactivation (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tumor-specific CD8+ T cells (1)
- tumor‐specific antigen (1)
- venetoclax (1)
- video capsule endoscopy (1)
- warfarin interruption (1)
Institute
- Medizinische Klinik und Poliklinik II (61) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 733297 (2)
- 19-COP-0031 (1)
- 641458 (1)
- 754658 (1)
- 847507 (1)
- 853988 (1)
- EU-1650-0006 (1)
We herein report the case of a 73‐year‐old male patient who was diagnosed with leukemic non‐nodal MCL. This patient had received six cycles of bendamustine, which resulted in a transient remission, and a second‐line therapy with ibrutinib, which unfortunately failed to induce remission. We started a treatment with single‐agent obinutuzumab at a dose of 20 mg on day 1, 50 mg on day 2‐4, 330 mg on day 5, and 1000 mg on day 6. The laboratory analysis showed a rapid decrease of leukocyte count. Four weeks later, we repeated the treatment with obinutuzumab at a dose of 1000 mg q4w and started a therapy with venetoclax at a dose of 400 mg qd, which could be increased to 800 mg qd from the third cycle. This combination therapy was well tolerated. The patient achieved a complete remission (CR) after three cycles of obinutuzumab and venetoclax. To date, the patient has a progression‐free survival of 17 months under ongoing obinutuzumab maintenance q4w. This is the first report about obinutuzumab and venetoclax induced CR in rituximab‐intolerant patient with an ibrutinib‐resistant MCL. This case suggests that obinutuzumab‐ and venetoclax‐based combination therapy might be salvage therapy in patients with ibrutinib‐resistant MCL.
Background
Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in RRMM.
Methods
We retrospectively analyzed data of 56 patients with RRMM who received Pom‐PAD‐Dara between September 2016 and May 2019.
Results
Patients were heavily pretreated with a median of four prior lines of therapy, including autologous and allogenic stem cell transplant in 50 (89%) and six (11%) patients, respectively. The overall response rate (ORR) was 78% and we observed partial remission, very good partial remission, and complete remission in 27 (48%), 13 (23%) and four (7%) patients, respectively. Median progression‐free survival was 7 months (95% CI, 3.3‐10.7) and the median overall survival was not reached at 24 months. Adverse events grade ≥ 3 were observed 41 (73%) patients and included neutropenia (n = 28, 50%), anemia (n = 22, 39%), thrombocytopenia (n = 21, 38%), and pneumonia (n = 6, 11%).
Conclusion
Pom‐PAD‐Dara represents a promising multiagent regimen in heavily pretreated RRMM patients with high ORR and an acceptable safety profile.
In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatment of relapsed/refractory (RR) MM, and early phase clinical trials have shown promising efficacy of CAR T cell therapy. Many patients with end stage RRMM regard CAR T cell therapy as their “last chance” and a “hope of cure”. However, severe adverse events (AEs) and even toxic death related to CAR T cell therapy have been observed. The management of AEs related to CAR T cell therapy represents a new challenge, as the pathophysiology is not fully understood and there is still no well-established standard of management. With regard to CAR T cell associated toxicities in MM, in this review, we will provide an overview of experience from clinical trials, pathophysiology, and management strategies.
Published experience with carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy and safety of carfilzomib containing therapy regimens in EMD. We retrospectively analyzed 45 patients with extramedullary RRMM treated with carfilzomib from June 2013 to September 2019. The median age at the start of carfilzomib was 64 (range 40–80) years. Twenty (44%) and 25 (56%) patients had paraosseous manifestation and EMD without adjacency to bone, respectively. The serological overall response rate (ORR) was 59%. Extramedullary response was evaluable in 33 patients, nine (27%) of them achieved partial remission (PR) (ORR = 27%). In 15 (33%) patients, we observed no extramedullary response despite serological response. The median progression-free survival (PFS) and overall survival (OS) were five (95% CI, 3.5–6.5) and ten (95% CI, 7.5–12.5) months, respectively. EMD without adjacency to bone was associated with a significantly inferior PFS (p = 0.004) and OS (p = 0.04) compared to paraosseous lesions. Carfilzomib based treatment strategies showed some efficacy in heavily pretreated patients with extramedullary RRMM but could not overcome the negative prognostic value of EMD. Due to the discrepancy between serological and extramedullary response, evaluation of extramedullary response using imaging is mandatory in these patients.
Utilizing 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT), we performed this pilot study to evaluate the link between cytogenetic/genomic markers and imaging patterns in relapsed/refractory (RR) multiple myeloma (MM). We retrospectively analyzed data of 24 patients with RRMM who were treated at our institution between November 2018 and February 2020. At the last relapse/progression, patients had been treated with a median of three (range 1–10) lines of therapy. Six (25%) patients showed FDG avid extramedullary disease without adjacency to bone. We observed significantly higher maximum standardized uptake values (SUV\(_{max}\)) in patients harboring del(17p) compared with those without del(17p) (p = 0.025). Moreover, a high SUV\(_{max}\) of >15 indicated significantly shortened progression-free survival (PFS) (p = 0.01) and overall survival (OS) (p = 0.0002). One female patient exhibited biallelic TP53 alteration, i.e., deletion and mutation, in whom an extremely high SUV\(_{max}\) of 37.88 was observed. In summary, this pilot study suggested a link between del(17p)/TP53 alteration and high SUV\(_{max}\) on 18F-FDG PET/CT in RRMM patients. Further investigations are highly warranted at this point.
This study aimed to explore the correlation between imaging patterns and clinical features in patients with smoldering multiple myeloma (SMM) who simultaneously underwent 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor positron emission tomography/computed tomography (PET/CT). We retrieved and analyzed clinical characteristics and PET imaging data of 10 patients with SMM. We found a significant correlation between bone marrow (BM) plasma cell (PC) infiltration and mean standardized uptake values (SUV\(_{mean}\)) of lumbar vertebrae L2-L4 on 11C-Methionine PET/CT scans (r = 0.676, p = 0.031) and 68Ga-Pentixafor PET/CT scans (r = 0.839, p = 0.002). However, there was no significant correlation between BM involvement and SUV\(_{mean}\) of lumbar vertebrae L2-L4 on 18F-FDG PET/CT scans (r = 0.558, p = 0.093). Similarly, mean target-to-background ratios (TBR\(_{mean}\)) of lumbar vertebrae L2-L4 also correlated with bone marrow plasma cell (BMPC) infiltration in 11C-Methionine PET/CT (r = 0.789, p = 0.007) and 68Ga-Pentixafor PET/CT (r = 0.724, p = 0.018) PET/CT. In contrast, we did not observe a significant correlation between BMPC infiltration rate and TBR\(_{mean}\) in 18F-FDG PET/CT (r = 0.355, p = 0.313). Additionally, on 11C-Methionine PET/CT scans, we found a significant correlation between BMPC infiltration and TBR\(_{max}\) of lumbar vertebrae L2-L4 (r = 0.642, p = 0.045). In conclusion, 11C-Methionine and 68Ga-Pentixafor PET/CT demonstrate higher sensitivity than 18F-FDG PET/CT in detecting BM involvement in SMM.
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
(2020)
Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRAS\(^{p.G12C}\) entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, including the less common exon-4 mutations. For the current study, the coding regions of KRAS were deep-sequenced in 80 newly diagnosed MM patients, uniformely treated with three cycles of bortezomib plus dexamethasone and cyclophosphamide (VCD)-induction, followed by high-dose chemotherapy and autologous stem cell transplantation. Moreover, the functional impact of KRAS\(^{p.G12A}\) and the exon-4 mutations p.A146T and p.A146V on different survival pathways was investigated. Specifically, KRAS\(^{WT}\), KRAS\(^{p.G12A}\), KRAS\(^{p.A146T}\), and KRAS\(^{p.A146V}\) were overexpressed in HEK293 cells and the KRAS\(^{WT}\) MM cell lines JJN3 and OPM2 using lentiviral transduction and the Sleeping Beauty vector system. Even though KRAS-mutations were not correlated with survival, all KRAS-mutants were found capable of potentially activating MEK/ERK- and sustaining PI3K/AKT-signaling in MM cells.
Delayed natural killer (NK) cell reconstitution after allogeneic stem cell transplantation (alloSCT) is associated with a higher risk of developing invasive aspergillosis. The interaction of NK cells with the human pathogen Aspergillus (A.) fumigatus is mediated by the fungal recognition receptor CD56, which is relocated to the fungal interface after contact. Blocking of CD56 signaling inhibits the fungal mediated chemokine secretion of MIP-1α, MIP-1β, and RANTES and reduces cell activation, indicating a functional role of CD56 in fungal recognition. We collected peripheral blood from recipients of an allograft at defined time points after alloSCT (day 60, 90, 120, 180). NK cells were isolated, directly challenged with live A. fumigatus germ tubes, and cell function was analyzed and compared to healthy age and gender-matched individuals. After alloSCT, NK cells displayed a higher percentage of CD56\(^{bright}\)CD16\(^{dim}\) cells throughout the time of blood collection. However, CD56 binding and relocalization to the fungal contact side were decreased. We were able to correlate this deficiency to the administration of corticosteroid therapy that further negatively influenced the secretion of MIP-1α, MIP-1β, and RANTES. As a consequence, the treatment of healthy NK cells ex vivo with corticosteroids abrogated chemokine secretion measured by multiplex immunoassay. Furthermore, we analyzed NK cells regarding their actin cytoskeleton by Structured Illumination Microscopy (SIM) and flow cytometry and demonstrate an actin dysfunction of NK cells shown by reduced F-actin content after fungal co-cultivation early after alloSCT. This dysfunction remains until 180 days post-alloSCT, concluding that further actin-dependent cellular processes may be negatively influenced after alloSCT. To investigate the molecular pathomechansism, we compared CD56 receptor mobility on the plasma membrane of healthy and alloSCT primary NK cells by single-molecule tracking. The results were very robust and reproducible between tested conditions which point to a different molecular mechanism and emphasize the importance of proper CD56 mobility.
Background and Aims: Colonoscopy as standard procedure in endoscopy is often perceived as uncomfortable for patients. Patient's anxiety is therefore a significant issue, which often lead to avoidance of participation of relevant examinations as CRC-screening. Non-pharmacological anxiety management interventions such as music might contribute to relaxation in the phase prior and during endoscopy. Although music's anxiolytic effects have been reported previously, no objective measurement of stress level reduction has been reported yet. Focus of this study was to evaluate the objective measurement of the state of relaxation in patients undergoing colonoscopy.
Methods: Prospective study (n = 196) performed at one endoscopic high-volume center. Standard colonoscopy was performed in control group. Interventional group received additionally self-chosen music over earphones. Facial Electromyography (fEMG) activity was obtained. Clinician Satisfaction with Sedation Instrument (CSSI) and Patients Satisfaction with Sedation Instrument (PSSI) was answered by colonoscopists and patients, respectively. Overall satisfaction with music accompanied colonoscopy was obtained if applicable.
Results: Mean difference measured by fEMG via musculus zygomaticus major indicated a significantly lower stress level in the music group [7.700(±5.560) μV vs. 4.820(±3.330) μV; p = 0.001]. Clinician satisfaction was significantly higher with patients listening to music [82.69(±15.04) vs. 87.3(±15.02) pts.; p = 0.001]. Patient's satisfaction was higher but did not differ significantly.
Conclusions: We conclude that self-chosen music contributes objectively to a reduced stress level for patients and therefore subjectively perceived satisfaction for endoscopists. Therefore, music should be considered as a non-pharmacological treatment method of distress reduction especially in the beginning of endoscopic procedures.
Due to the rapidly increasing development and use of cellular products, there is a rising demand for non-animal-based test platforms to predict, study and treat undesired immunity. Here, we generated human organotypic skin models from human biopsies by isolating and expanding keratinocytes, fibroblasts and microvascular endothelial cells and seeding these components on a collagen matrix or a biological vascularized scaffold matrix in a bioreactor. We then were able to induce inflammation-mediated tissue damage by adding pre-stimulated, mismatched allogeneic lymphocytes and/or inflammatory cytokine-containing supernatants histomorphologically mimicking severe graft versus host disease (GvHD) of the skin. This could be prevented by the addition of immunosuppressants to the models. Consequently, these models harbor a promising potential to serve as a test platform for the prediction, prevention and treatment of GvHD. They also allow functional studies of immune effectors and suppressors including but not limited to allodepleted lymphocytes, gamma-delta T cells, regulatory T cells and mesenchymal stromal cells, which would otherwise be limited to animal models. Thus, the current test platform, developed with the limitation that no professional antigen presenting cells are in place, could greatly reduce animal testing for investigation of novel immune therapies.